Literature DB >> 9197332

Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo- and/or bromodeoxyuridine.

A Raza1, S Alvi, L Broady-Robinson, M Showel, J Cartlidge, S D Mundle, V T Shetty, R Z Borok, S E Dar, H K Chopra, L Span, A Parcharidou, C Hines, S Gezer, P Venugopal, J Loew, J Showel, D Alston, B Hernandez, S Rifkin, E Robin, R Shah, S A Gregory.   

Abstract

Sixty-eight patients with myelodysplastic syndromes (MDS) received sequential infusions of iodo- and/or bromodeoxyuridine for cell kinetic analysis. Bone marrow biopsy sections were treated by appropriate antibodies and a labeling index (LI), duration of S-phase (Ts), and total cell cycle time (Tc) of myeloid cells were determined. The mean LI was 28.4%, Ts was 11.8 hours and Tc was 40.7 hours. The %LI decreased as the disease evolved from refractory anemia toward transformation to acute leukemia (p = 0.04). Double-labeling of biopsy sections for apoptosis and proliferation showed that 30-90% of S-phase cells in MDS patients were simultaneously apoptotic or "antonymous." We conclude that MDS are highly proliferative disorders in which the ineffective hematopoiesis is probably the result of excessive apoptosis rather than slow proliferation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9197332

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  8 in total

Review 1.  Myelodysplasia and apoptosis: new insights into ineffective erythropoiesis.

Authors:  A A van de Loosdrecht; E Vellenga
Journal:  Med Oncol       Date:  2000-02       Impact factor: 3.064

2.  Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.

Authors:  S Jilg; V Reidel; C Müller-Thomas; J König; J Schauwecker; U Höckendorf; C Huberle; O Gorka; B Schmidt; R Burgkart; J Ruland; H-J Kolb; C Peschel; R A J Oostendorp; K S Götze; P J Jost
Journal:  Leukemia       Date:  2015-07-08       Impact factor: 11.528

3.  Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome.

Authors:  Krishnan Allampallam; Vilasini Shetty; Suneel Mundle; Diya Dutt; Howard Kravitz; Poluru L Reddy; Sairah Alvi; Naomi Galili; Gurveen S Saberwal; Shalini Anthwal; Maliha W Shaikh; Aaron York; Azra Raza
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

Review 4.  The role of apoptosis in the pathogenesis of the myelodysplastic syndromes.

Authors:  Jane E Parker; Ghulam J Mufti
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

5.  Single-cell mass cytometry adapted to measurements of the cell cycle.

Authors:  Gregory K Behbehani; Sean C Bendall; Matthew R Clutter; Wendy J Fantl; Garry P Nolan
Journal:  Cytometry A       Date:  2012-06-12       Impact factor: 4.355

6.  Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes.

Authors:  Wendy W Pang; John V Pluvinage; Elizabeth A Price; Kunju Sridhar; Daniel A Arber; Peter L Greenberg; Stanley L Schrier; Christopher Y Park; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-06       Impact factor: 11.205

Review 7.  The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes.

Authors:  Azra Raza; Naomi Galili
Journal:  Nat Rev Cancer       Date:  2012-12       Impact factor: 60.716

8.  Innovative analyses support a role for DNA damage and an aberrant cell cycle in myelodysplastic syndrome pathogenesis.

Authors:  David R Head; James W Jacobberger; Claudio Mosse; Madan Jagasia; William Dupont; Stacey Goodman; Leanne Flye; Andrew Shinar; Sara McClintock-Treep; Greg Stelzer; Robert Briggs; Keith Shults
Journal:  Bone Marrow Res       Date:  2011-06-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.